(Q41911824)

14 October 2017

title

Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer (English)

1 reference

14 October 2017

0 references

Burkhardt Seifert

4

0 references

Alexander Knuth

7

object named as

Alexander Knuth

1 reference

14 October 2017

Panagiotis Samaras

1

1 reference

14 October 2017

Marina Tusup

2

1 reference

14 October 2017

Thi Dan Linh Nguyen-Kim

3

1 reference

14 October 2017

Helga Bachmann

5

1 reference

14 October 2017

Roger von Moos

6

1 reference

14 October 2017

Steve Pascolo

8

1 reference

14 October 2017

publication date

4 October 2017

1 reference

Cancer Chemotherapy and Pharmacology

14 October 2017

published in

1 reference

14 October 2017

cites work

Cancer Statistics, 2017.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis o

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

Blocking TLR2 activity attenuates pulmonary metastases of tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3446-Y

10.1007/S00280-017-3446-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

14 October 2017

1092059439

0 references

1 reference